Author:
Deavin Andrew,Hossain Aliyah,Colmagne-Poulard Isabelle,Wong Kum Cheun,Perea-Vélez Mónica,Cappellini Sonia,Ausborn Susanne,Meillerais Sylvie,Bourguignon Céline
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Harris R, Vanhooren M, Follmann K, et al. An evaluation of postapproval CMC change timelines. Pharm Eng September/October. 2023;2023:26–33.
2. Vinther A, Ramnarine E, Gastineau T, et al (2024). Approaches to Design an Efficient, Predictable Global Post-approval Change Management System that Facilitates Continual Improvement and Drug Product Availability. Therapeutic Innovation and Regulatory Science. Approaches to Design an Efficient, Predictable Global Post-approval Change Management System that Facilitates Continual Improvement and Drug Product Availability - PubMed (nih.gov). Online ahead of print. Accessed 26 March 2024.
3. International Council on Harmonisation. ICH Q12 (Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management). Q12_Guideline_Step4_2019_1119.pdf (ich.org). Accessed 6 February 2023.
4. Center for Innovation in Regulatory Science (CIRS). 2021 Project Report - Monitoring Implementation and Adherence to ICH Guidelines. 2021 Project report – Monitoring implementation and adherence to ICH guidelines – CIRS (cirsci.org) - accessed 21 December 2023
5. ICMRA (2022). Collaborative Pilot Update | International Coalition of Medicines Regulatory Authorities (ICMRA) – Accessed 21 December 2023